Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Apalutamide |
Synonyms | |
Therapy Description |
Erleada (apalutamide) is a second-generation antiandgrogen, that binds to the androgen receptor (AR) and inhibits downstream signaling, potentially resulting in decreased growth of AR-expressing tumors (PMID: 22266222, PMID: 23337756). Erleada (apalutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (FDA.gov). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Apalutamide | Erleada | ARN-509|JNJ-56021927 | Hormone - Anti-androgens 47 | Erleada (apalutamide) is a second-generation antiandgrogen, that binds to the androgen receptor (AR) and inhibits downstream signaling, potentially resulting in decreased growth of AR-expressing tumors (PMID: 22266222, PMID: 23337756). Erleada (apalutamide) is FDA approved for use in patients with non-metastatic castration-resistant prostate cancer and metastatic castration-sensitive prostate cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03899077 | Phase II | Triptorelin Goserelin Degarelix Leuprolide Apalutamide | Radiotherapy Combined With a LHRH (Ant)Agonist Versus Apalutamide in Patients With Biochemical Recurrence After RP (SAVE) | Unknown status | BEL | 0 |
NCT03503344 | Phase II | Apalutamide | Apalutamide With or Without Stereotactic Body Radiation Therapy in Treating Participants With Castration-Resistant Prostate Cancer (PILLAR) | Recruiting | USA | 0 |
NCT02489318 | Phase III | Apalutamide | A Phase 3 Study of JNJ-56021927 Plus Androgen Deprivation Therapy (ADT) Versus ADT in Participants With Low-Volume mHSPC | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CAN | AUS | 15 |
NCT03279250 | Phase II | Goserelin Triptorelin Abiraterone + Apalutamide + Prednisone Leuprolide Apalutamide | Effects of Apalutamide Plus LHRH Agonist or Apalutamide Plus Abiraterone Acetate Plus LHRH Agonist for Six Months for Prostate Cancer Patients at High Risk for Recurrence | Completed | USA | 0 |
NCT02578797 | Phase I | Apalutamide | A JNJ-56021927 (ARN-509) QT/QTc Study | Completed | USA | GBR | CAN | 2 |
NCT04523207 | Phase II | Apalutamide | A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases | Active, not recruiting | USA | 0 |
NCT01790126 | Phase II | Apalutamide | The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer | Completed | USA | 0 |
NCT05191680 | Phase III | Apalutamide | TherApeutics in Early ProState Cancer (TAPS02) | Recruiting | GBR | 0 |
NCT04947254 | Phase II | Apalutamide Abiraterone + Apalutamide + Niraparib + Prednisone | Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer | Recruiting | USA | 0 |
NCT01946204 | Phase III | Apalutamide | A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer (SPARTAN) | Active, not recruiting | USA | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS | 16 |
NCT04295447 | Phase II | Apalutamide | Adjuvant Apalutamide in Subjects With High-risk Localized or Locally Advanced Prostate Cancer After Radical Prostatectomy (ADAM) | Recruiting | DEU | AUT | 0 |
NCT03767244 | Phase III | Apalutamide Abiraterone + Apalutamide Prednisone | A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy | Active, not recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | AUS | 10 |
NCT05521698 | Phase I | Apalutamide | Effects of Apalutamide on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer | Not yet recruiting | USA | 0 |
NCT02906605 | Phase II | Apalutamide Apalutamide + JNJ-64041809 | A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer | Withdrawn | USA | 0 |
NCT05884398 | Phase III | Apalutamide | A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC (LIBERTAS) | Recruiting | USA | CAN | AUS | 1 |
NCT05534646 | Phase II | Apalutamide Apalutamide + Carotuximab | Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer | Recruiting | USA | 0 |
NCT02721979 | Phase II | Apalutamide | ARN-509 in Treating Patients With Prostate Cancer Who Are in Active Surveillance | Terminated | USA | 0 |
NCT04530552 | Phase II | Apalutamide | Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland | Recruiting | USA | 0 |
NCT03088124 | Phase II | Apalutamide | Active Surveillance With or Without Apalutamide Treatment in Low Risk Prostate Cancer (PC-ARN) | Unknown status | FRA | 0 |
NCT03412396 | Phase II | Apalutamide | Single Arm Study of 6-Months Neoadjuvant ARN-509 Prior to Radical Prostatectomy | Active, not recruiting | USA | 0 |
NCT05683964 | Phase I | Apalutamide Darolutamide Enzalutamide | Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression | Recruiting | USA | 0 |
NCT04812366 | Phase II | Abiraterone + Apalutamide + Prednisone Apalutamide Abiraterone + Prednisone Apalutamide + Atezolizumab Abiraterone + Docetaxel + Prednisone Abiraterone + Niraparib + Prednisone | Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer (GUNS) | Recruiting | USA | CAN | 0 |
NCT05422911 | Phase II | Enzalutamide Abiraterone Apalutamide | Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer. | Not yet recruiting | USA | 0 |
NCT06067269 | Phase II | Apalutamide | Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial (HEATWAVE) | Not yet recruiting | USA | 0 |
NCT05790213 | Phase II | Apalutamide | Focal Prostate Ablation With Androgen Deprivation and Novel Hormonal Therapy for Intermediate Risk Prostate Cancer | Recruiting | USA | 0 |
NCT02949284 | Phase II | Apalutamide Abiraterone + Apalutamide + Prednisone | Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery | Recruiting | USA | 0 |
NCT03371719 | Phase II | Apalutamide | Radiation Therapy With or Without Apalutamide in Treating Patients With Stage III-IV Prostate Cancer | Active, not recruiting | USA | CAN | 0 |